EXAS vs RNXT · rev $2.76B vs rev $266.0K
EXACT Sciences Corporation (EXAS) versus RenovoRx Inc (RNXT) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
RenovoRx Inc (RNXT) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported RNXT revenue for 2025-09-30 was $266.0K. Net income was -$2.9M. Revenue was down 37.0% from 2025-06-30 to 2025-09-30. RNXT currently screens at market cap $47.0M.
EXAS currently screens at market cap $20.03B. RNXT currently screens at market cap $47.0M.
Not investment advice. Open the EXAS and RNXT stock pages for the full models.
Not investment advice.